HERZLIYA, Israel, April 17, 2012 /PRNewswire/ --
XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced yesterday that Dr. Ben-Zion Weiner, Ph.D., has been named as director of the Company's board of directors.
Since 2012, Dr. Weiner serves as Special Advisor to the Chief Executive Officer of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA, TASE: TEVA.TA). Dr. Weiner brings to XTL his vast experience in pharmaceutical development, from R&D to regulatory approval. Dr. Weiner has been with Teva for 36 years.
"I am very pleased to have joined XTL as member of the board of directors and I will use my R&D expertise in the product development of the Company," said Dr. Weiner.Dr. Weiner received his Ph.D. in chemistry from the Hebrew University of Jerusalem, where he also earned B.Sc. and M.Sc. degrees, followed by a post-doctoral fellowship at Schering-Plough Corporation in the United States. He was granted the Rothschild Prize for Innovation/Export twice, in 1989 for the development of Alpha D3 for dialysis and osteoporosis, and in 1999 for the development of Copaxone® for multiple sclerosis. David Grossman, XTL's CEO commented "Dr. Weiner brings with him 40 years of drug development experience in the pharmaceutical industry, with large number of New Drug Application approvals under his leadership. We are very pleased that he joined our board, and believe his experience will be extremely valuable as we progress with our clinical development programs." About XTL Biopharmaceuticals, Ltd. ("XTL") XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV